Shanghai, China – 27 March, 2015 – Shanghai MicroPort Medical (Group) Co ("MicroPort") recently attended China Interventional Therapeutics ("CIT"), the biggest International academic congress in the field of interventional cardiology in China, which was held in Beijing from March 19 to March 22. During the event, MicroPort organized several satellite symposiums to promote its in-house developed third-generation drug-eluting stent ("DES") Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Firebird2™ Rapamycin-Eluting Coronary CoCr Stent ("Firebird2™").
On March 21, MicroPort hosted a satellite symposium themed "Conquest of Challenges, Confidence Based Evidence – Update on TARGET Clinical Program." Cardiologist Runlin Gao of Fuwai Hospital, Professor Weifeng Shen of Shanghai Ruijin Hospital, Professor Yundai Chen of Chinese PLA General Hospital, and Dr. Martin B. Leon, Director of Center for Interventional Vascular Therapy of Columbia University, chairman of TCT and principal co-investigator of TARGET trial, were invited to chair the symposium. After introducing Firehawk®'s features, Dr. Martin B. Leon commented that Firehawk® is a safe, effective, and easy-to-use DES. Cardiologist Runlin Gao then presented the latest data of TARGET trial – TARGETⅡthree-year study data show that the rate of Target Lesion Failure ("TLF") is as low as 6.5%, proving Firehawk®'s efficacy and safety in treatment of complex cardiovascular diseases.
Firehawk® gained CE Mark approval from the European Notified Body on January 23, 2015. On the basis of existing research, MicroPort has launched a large-scale, randomized trial - TARGET All Comer - in Europe, to further study Firehawk®'s clinical performance. William Wijns, TARGET All Comer's principal investigator, introduced the theoretical foundations and design scheme of TARGET All Comer to people in attendance.
In another satellite symposium held on March 21, MicroPort shared "Ten Years' Journey of Firebird Series" with participants. Yan li, Deputy Director of Cardiology Department of Xijing Hospital, spoke highly of Firebird2™'s performance in treatment of PCI in diabetes. Three international experts later presented Firebird2™'s performance in treatment of complex PCI, proving its excellent efficiency and safety.